Rectal Cancer
Conditions
Brief summary
This study aimed to assess efficacy of ArtiSential® in reducing laparoscopic rectal cancer surgery duration. We retrospectively reviewed the data of patients who underwent laparoscopic low or ultralow anterior resection for primary mid-to-low rectal cancer, performed by a single surgeon in 2012-2022. Patients were divided into groups, use group vs. non-use group, based on the use or non-use of the ArtiSential®. The total mesorectal excision quality and resection margin status did not differ between the groups. ArtiSential® reduced operative time without impairing surgical quality or oncologic outcomes.
Interventions
DEVICEArtiSential®
Articulated laparoscopic device made by Livsmed Co, South Korea.
Sponsors
Seoul National University Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
Yes
Inclusion criteria
* mid-to-low rectal caner (witing 10cm of the anal verge) * laparoscopic surgery
Exclusion criteria
* combined surgery * recurrent rectal cancer surgery
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Operation time | 0 week | To determine whether the use of articulated device can shorten total operative time |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Long-term Survival | 2 year | 2 year recurrence free survival and 2 year overall survival |
| Anastomotic leakage (postop outcome) | 4 weeks | anastomotic leakage within one month |
| TME quality (Operative outcome) | 0 weeks | Quality of total mesorectal excision to compare quality of surgery |
Countries
South Korea
Outcome results
None listed